Aerovate Therapeutics, Inc. (AVTE) Misses Q1 EPS by 7c, provides guidance

Aerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q1 EPS of ($0.83), $0.07 worse than the analyst estimate of ($0.76).

Financial guidance: We expect that our cash, cash equivalents and short-term investments will be sufficient to fund our operations into 2026, based on our current operating plan.

For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c